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2Abstract
Since December 2019 the novel coronavirus SARS-CoV-2 has been identified as the cause of the 
pandemic Covid 19. Early symptoms overlap with other common conditions such as common cold 
and Influenza, making early screening and diagnosis are crucial goals for health practitioners. The 
aim of the study was to use machine learning, an artificial neural network (ANN) and a simple 
statistical test to identify SARS-CoV-2 positive patients from full blood counts without knowledge of 
symptoms or history of the individuals. The dataset included in the analysis and training contains 
anonymized full blood count results from patients seen at the Hospital Israelita Albert Einstein, at 
São Paulo, Brazil, and who had samples collected to perform the SARS-CoV-2 rt-PCR test during a 
visit to the hospital. Patient data was anonymised by the hospital, clinical data was standardized to 
have a mean of zero and a unit standard deviation. This data was made public with the aim to allow 
researchers to develop ways to enable the hospital to rapidly predict and potentially identify SARS-
CoV-2 positive patients.
We find that with full blood counts random forest, shallow learning and a flexible ANN model predict 
SARS-CoV-2 patients with high accuracy between populations on regular wards (AUC = 93-94%) and 
those not admitted to hospital or in the community (AUC = 80-86%). Here AUC is the Area Under the 
receiver operating characteristics Curve and a measure for model performance. Moreover, a simple 
linear combination of 4 blood counts can be used to have an AUC of 85% for patients within the 
community. The normalised data of different blood parameters from SARS-CoV-2 positive patients 
exhibit a decrease in platelets, leukocytes, eosinophils, basophils and lymphocytes, and an increase 
in monocytes. 
SARS-CoV-2 positive patients exhibit a characteristic immune response profile pattern and changes 
in different parameters measured in the full blood count that are detected from simple and rapid 
blood tests. While symptoms at an early stage of infection are known to overlap with other common 
conditions, parameters of the full blood count can be analysed to distinguish the viral type at an 
earlier stage than current rt-PCR tests for SARS-CoV-2 allow at present. This new methodology has 
potential to greatly improve initial screening for patients where PCR based diagnostic tools are 
limited.
Key Words:
SARS-CoV-2; Machine Learning; Artificial Neural Network (ANN), Screening; Full blood count; 
Leukocytes; Monocytes
Highlights:
1. Early SARS-CoV-2 prediction from monocytes-leukocytes-eosinophils variable: AUC 84%
2. Prediction in regular ward using machine learning from full blood count: AUC 94%
3. Predominance of monocytes in SARS-CoV-2 positive patients similar to SARS and MERS
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3Introduction
The World Health Organization (WHO) characterized the Covid-19 pandemic on 11th March 2020 1 . 
The symptoms of Covid-19 induced by the novel pathogen SARS-CoV-2, are difficult to differentiate 
from other common infections in a large proportion of those infected. It is estimated that about 40% 
of cases will experience mild disease (cough, fever), 40% experience moderate disease (bilateral 
pneumonia), 15% develop severe disease and 5% will have critical disease 2. A recommendation by 
the WHO has been to conduct early screening of patients to identify, isolate and track those infected 
and prevent transmission 2.
Reverse transcription Polymerase Chain Reaction (rt-PCR) based methodologies have been the gold 
standard in confirming that the individual presenting with Covid-19 has active viral shedding of 
SARS-CoV-23-4 . However, the ability to conduct wide scale testing of patients has been limited by a 
number of factors including suitable resources for rt-PCR based testing for the presence of SARS-
CoV-2. In addition, the standard test used has an 80% accuracy (compared to chest CT scan results) 5, 
which may depend on the specific level of viral shedding by any individual at the time of sample test. 
Moreover, the time from sample collection to informing the patient is estimated to take many hours 
to several days according to the systems in place. These complex issues hand in hand with the wide-
ranging symptoms presenting in patients and the discrepant results between chest CT, symptoms 
and rt-PCR results 5, indicates that testing for the direct presence of virus requires significant 
improvement.
While highly specific tests for SARS-CoV-2 are under development using CRISPR6  and Biosensors 7-8 , 
these innovative applications will require highly specialised equipment and resources. This will 
negatively affect less affluent areas that will be unable to access these technologies in the short time 
frame in order to contain the pandemic. Therefore, there is a global challenge to enable screening  
without the need for sophisticated equipment and resources.
Machine learning and artificial intelligence approaches are rapidly being developed to aid clinical 
procedures in the current pandemic, such as predicting the specificity of new therapies9  and 
diagnosing COVID 19 patients from radiographic patterns on CT scans10 .
In the current study we focused on predicting whether a person is SARS-CoV-2 positive or negative in 
the early stage of the disease. The approach taken is based on the reported limitation to conduct rt- 
PCR tests and the need to quickly differentiate between individuals presenting with similar 
symptoms as seen between COVID 19 and other common infections. The dataset used here comes 
from a public challenge by mindstream-ai11  to use Artificial Intelligence to predict the test result for 
SARS-CoV-2 (positive/negative) solely from complete blood tests.
The Hospital Israelita Albert Einstein is located in the state of Sao Paulo, Brazil, with a population of 
12 million people had 477 confirmed cases of Covid 19 and 30 associated deaths by the 23rd March 
2020. The hospital publicly released full blood counts 12 from 598 anonymised patients, along with 
the rt-PCR result for SARS-CoV-2 and their age quantile (symptoms or patient history were not 
released). Here we present evidence that patients having SARS-CoV-2 can be identified by Random 
Forest machine learning and artificial neural networks (ANN) to patients not admitted to hospital 
(community) and to patients in a regular ward setting through recognition of the altered immune 
cell profile. These will allow for a rapid early screening purely based on the blood profile.
4Methods
Patient Dataset
All data processed in this study is published on a public forum12 , as part of a challenge to accelerate 
approaches to combat the spread of SARS-CoV-2. This dataset contains anonymized data from 
patients seen at the Hospital Israelita Albert Einstein, at São Paulo, Brazil, and who had samples 
collected to perform the SARS-CoV-2 rt-PCR and additional laboratory tests during a visit to the 
hospital. All data were anonymized following the best international practices and 
recommendations11. All clinical data were standardized to have a mean of zero and a unit standard 
deviation.
Data provided included age (percentile group), outcome from rt-PCR SARS-CoV-2 test and standard 
full blood count: hematocrit, haemoglobin, platelets, mean platelet volume (MPV), red blood cells 
(RBC), lymphocytes, mean corpuscular haemoglobin concentration (MCHC), leukocytes, basophils, 
neutrophils, mean corpuscular haemoglobin (MCH), eosinophils, mean corpuscular volume (MCV), 
monocytes and red blood cell distribution width (RBCDW) 13.
The full dataset released included 5644 individual patients tested between the 28th of March 2020 
and 3rd of April 2020, of which 598 full blood count results were used for statistical analysis. The 
remaining 5046 results were not used due to lack of full blood count data. 
Without in-depth data on the timeline of the tests performed in the duration of the infection, 
analysis was performed on the basis of severity according to the location of the patient within the 
hospital system. The blood counts are from four classifications of patients: Community (patients not 
admitted to hospital), Regular Ward, Semi Intensive Care and Intensive Care Unit (ICU) (Table 1). 
Table 1: Sao Paulo Dataset groups; only datasets from patients with full blood counts and rt-PCR 
SARS-CoV-2 outcome included; Pathogen test conducted on 356 subset of the 598 tested for SARS-
CoV-2.
Number of 
patients
Community Regular Ward Semi Intensive 
Unit
Intensive 
Care
Total
SARS-CoV-2 
negative
431
(92%)
31
(54%)
34
(81%)
21
(72%)
517
(86%)
SARS-CoV-2 
positive
39
(8%)
26
(46%)
8
(19%)
8
(28%)
81
(14%)
Diagnosis of other 
pathogens (non 
SARS-CoV-2)
149 12 17 12 188
5Patients that are in semi-intensive and intensive care units are excluded from our modelling, so as to 
ensure prediction is based on early indicators. Also neutrophils are not included, since this is not 
reported for all 598 patients. Furthermore, we exclude age from our modelling.
There is a large imbalance of positive (8%) vs negative (92%) SARS-CoV-2 patients in the community . 
As a result it is more informative to test separately for the specificity (%-ge of negative patients 
correctly identified as negative) and the sensitivity (%-ge of positive patients correctly identified as 
positive) rather than solely the total accuracy.
Of the 598 complete counts analysed, 367 patients had also been tested for other pathogens: 
Adenovirus, Bordetella pertussis, Chlamydophila pneumoniae, Coronavirus 229E, Coronavirus HKU1, 
Coronavirus NL63, Coronavirus OC43, Inf A H1N1 2009, Influenza A, Influenza B, Metapneumovirus, 
Parainfluenza 1, Parainfluenza 2, Parainfluenza 3, Parainfluenza 4, Respiratory Syncytial Virus or 
Rhinovirus Enterovirus.
Model definitions: random forest and Lasso based regularized generalized 
linear models and artificial neural network
For our 2-class (SARS-CoV-2 positive vs negative) classification we employ several machine learning 
and artificial network models.
For the machine learning models we apply Random Forest 14-16 and Lasso-elastic-net regularized 
generalized linear (glmnet) models for classification. Random forest as a classifier is based on several 
decision trees. To classify a new object, each decision tree provides a classification for input data and 
the random forest uses the mode of those classification to decide on the class. 
In this paper, glmnet, on the other hand, fits a traditional logistic model. But instead of using all the 
predictors, it uses a regularized path to select the most important variables and only use them in the 
logistic regression. For both these methods, we present results for 10-fold cross-validation and their 
corresponding variable importance plots17.
Furthermore, an artificial neural network (ANN) 13 model is defined with 14 input parameters and 
three hidden layers and trained for 100 epochs. The classification performance of the ANN model is 
evaluated with stratified 10-fold cross validation.
Model performance measures
The performance of each model is expressed in terms of AUC, sensitivity, specificity and accuracy. 
They are defined as follows: sensitivity is the fraction of the SARS-CoV-2 positive patients correctly 
identified; specificity is the fraction of SARS-CoV-2 negative patients correctly identified as such; 
accuracy is the total number of patients correctly identified. By lowering the threshold of detecting 
SARS-CoV-2 positive patients, the sensitivity can increase at the expense of specificity. Hence we also 
look at the commonly employed AUC. This is the area under the receiver-operating characteristics 
curve; the curve when plotting sensitivity vs (1-specificity) upon changing the threshold. The AUC, 
also known as the Wilcoxon-Mann-Whitney statistic, is the probability that a SARS-CoV-2 positive 
patient is higher ranked than a SARS-CoV-2 negative patient. A higher AUC generally implies a better 
performing model. We note that the drawback of using accuracy alone is that, in an unbalanced set 
of mainly SARS-CoV-2 negative patients (as is the case in the community dataset), the accuracy can 
be high using zero sensitivity.
6Results
Statistical analysis
Significant differences (p<0.05) between 9 of the 15 blood count parameters were shown between 
patients in a regular ward setting who tested positive or negative to SARS-CoV-2 presence (Figure 1). 
In order of importance (lower p) for the significant increased values for SARS-CoV-2 positive 
patients: MPV > RBC > lymphocytes > hematocrit > hemoglobin. The decreased values are 
eosinophils > leukocytes > platelets. For community-patients we found statistically significant 
differences (p<0.05) in 6 blood count parameters; the increased values are monocytes > MPV, while 
leukocytes > platelets > neutrophils > eosinophils show a significant decrease for SARS-CoV-2 
positive patients.
7Figure 1 Box plots showing median and 1st/3rd quartile of individual parameters of the full blood 
counts categorized by whether tested positive (red box) or negative (blue box) by the rt-PCR test for 
SARS-CoV-2 and by whether they remained in the community or were admitted in the regular ward. 
MPV; mean platelet volume, RBC; red blood cells, RBCDW; red blood cell distribution width. The p-
values are tests of equality of population using the Wilcoxon rank sum test, where p<0.05 implies 
statistically significant difference between the populations. 
8Modelling
Among the 598 patients with complete blood profiles, 57 were admitted in the regular ward (26 
tested rt-PCR positive to SARS-CoV-2, and 31 negative). Furthermore, a total of 470 patients were 
not admitted to the hospital (39 tested positive for SARS-CoV-2 and 431 negative). We will report 
model predictions for both sets of patients.
The defined ANN model for the regular ward patients produces an average classification accuracy of 
90% over stratified 10-fold cross-validation. The Receiver operating characteristic (ROC) curves for all 
10 folds and the values of area under the curve (AUC) are presented in Figure 2a, along with the 
average AUC (0.93±0.10). The normalized confusion matrix, corresponding to fold 0, is presented in 
Figure 2b.
Figure 2a. The ROC curve of the defined ANN model over patients admitted to regular ward; b. The 
normalized confusion matrix, corresponding to fold 0 (corresponds to the worst value of AUC). ROC: 
Receiver operating characteristic; AUC: area under the curve.
The defined ANN model for the community ward produces an average classification accuracy of 89% 
over stratified 10-fold cross-validation. The ROC curves for all 10-folds produce an average AUC of 
0.77±0.08, while the sensitivity and specificity indices are estimated as 0.28 and 0.95, respectively. 
Since the imbalance between two classes in the dataset (positive/negative = 0.09) degrades the 
performance of the defined ANN model, the Synthetic Minority Oversampling Technique (SMOTE) 18 
is adapted for balancing the two classes in the training dataset. The stratified 10-fold cross-validation 
technique is again incorporated and it is repeated for 10 times. The average accuracy, AUC, 
sensitivity, and specificity are estimated as 0.87, 0.80, 0.43, and 0.91, respectively. The ROC curves 
and the values of AUC for one repetition of the stratified 10-fold cross-validation are presented in 
Figure 3a, along with the average AUC (0.80±0.09). The normalized confusion matrix, corresponding 
to fold 8, is presented in Figure 3b.
9Figure 3a. The ROC curve of the defined ANN model over patients not admitted to the hospital 
(community); b. The normalized confusion matrix, corresponding to fold 8 (corresponds to the worst 
value of AUC). ROC: Receiver operating characteristic; AUC: area under the curve.
 
Figure 4. Variable importance plot of (a) random forest and (b) glmnet classification of SARS-CoV-2 
positive patients who are in the regular hospital ward. The plot shows the importance of variables in 
building the respective predictive model. MPV; mean platelet volume, RBC; red blood cells, MCHC; 
mean corpuscular haemoglobin concentration, MCH; mean corpuscular haemoglobin, MCV; mean 
corpuscular volume, RBCDW; red blood cell distribution width.
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The results from the implementation of random forest and glmnet on the 57 patients in the regular 
ward gives an average AUC of 94% over 10 fold classification, while for the patients in the 
community the AUC is 84-86% . The full array of sensitivity, specificity and accuracy values for 
optimal choices of cutoff  for these two classifiers are given Table 2 and Table 3. As compared to the 
ANN, both Random Forest and glmnet provide more insight into the most important variables 
(Figure 4(a) and (b)) and a clear indication of how the decision has been obtained. Additionally, 
glmnet does a variable selection, by providing a much smaller stable set of variables among 14 highly 
correlated predictors.
Analysis of the top four variables according to glmnet that corresponded to patients in community 
(Supplementary Figure 1) and regular ward (Supplementary Figure 2) indicated a clear recognisable 
pattern. In particular to note in patients in the regular ward is in the decreased pool of leukocytes 
overall, increase in red blood cells, and in particular a significant decrease in eosinophils. Community 
patients having SARS-CoV-2 have distinctively high levels of monocytes and low levels of leukocytes.
In order to enable a rapid prediction model for clinics12 where clinicians may want to choose only 
two (Figure 5a) three (Figure 5b) or four parameters (Figure 5c), the 
monocytes/leukocytes/eosinophils/platelets trends in Supplementary Figure 1 and 2 and Figure 1 
were analysed by adding monocytes and subtracting leukocytes, eosinophils and platelets. This 
difference indicates little overlap between patients who test positive and negative for SARS-CoV-2, 
however it must be noted that this is a simple additive formula based on normalised data.
For example a simple logistic regression (LR) with derived variable y=monocytes - leukocytes - 
eosinophils - platelets, shows this blood characteristic can predict the Covid test outcome with an 
average AUC = 85% over 10 fold cross-validation among the patients in the community, and AUC = 
81% for patients in regular ward. 
The model predictions from ANN, Random Forest, glmnet and the formula: monocytes - leukocytes - 
eosinophils (and m-l-e-p) are summarized in Table 2 and Table 3.
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Figure 5. Box plots of blood characteristics: a. monocytes - leukocytes (m-l) b. monocytes - 
leukocytes - eosinophils (m-l-e) and c. monocytes - leukocytes - eosinophils - platelets (m-l-e-p); all 
normalized values, categorized by whether tested negative (blue box) or positive (red box) to rt-PCR 
SARS-CoV-2 test, and whether they remained in the community or were admitted in the regular 
ward. All p-values are tests of equality of population using Wilcoxon rank sum test and suggest 
statistically significant difference.
Table 2. Model predictions for patients in regular ward testing for SARS-CoV-2 positive. Best 
indicator is given by *
Variables Classifier Sensitivity Specificity Accuracy AUC
14 different blood counts ANN 0.85 0.94 0.90 0.93
14 different blood counts RF 0.82 0.90 0.91 0.94
14 different blood counts GLMNET* 0.92 0.93 0.91 0.94
y=monocytes - leukocytes - 
eosinophils - platelets 
LR 0.85 0.77 0.81 0.81
y=monocytes - leukocytes - 
eosinophils 
LR 0.85 0.71 0.77 0.79
y=monocytes - leukocytes LR 0.65 0.58 0.61 0.65
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Table 3. Model predictions for patients not admitted to hospital (community) testing for SARS-CoV-2 
positive
Variables Classifier Sensitivity Specificity Accuracy AUC
14 different blood counts ANN 0.43 0.91 0.87 0.80
14 different blood counts RF 0.60 0.88 0.82 0.86
14 different blood counts GLMNET 0.65 0.81 0.81 0.84
y=monocytes - leukocytes - 
eosinophils - platelets 
LR 0.82 0.78 0.79 0.85
y=monocytes - leukocytes - 
eosinophils 
LR 0.82 0.79 0.79 0.84
y=monocytes - leukocytes LR 0.74 0.77 0.77 0.81
Of the patients testing for SARS-CoV-2 and complete blood tests, 366 patients were tested for other 
pathogens, of which 188 patients were diagnosed with other infections, to note Rhinovirus and 
Influenza B (Table 4). Collectively, 51% tested positive for: Respiratory Syncytial Virus, Influenza A, 
Influenza B, Parainfluenza 1, Coronavirus NL63, Rhinovirus Enterovirus, Coronavirus HKU1, 
Parainfluenza 3, Chlamydophila pneumonia, Adenovirus, Parainfluenza 4, Coronavirus 229E, 
Coronavirus OC43, Influenza A H1N1 2009, Bordetella pertussis, Metapneumovirus and 
Parainfluenza 2. The similar presentation of many of these infections to COVID19 may however be 
differentiated by the clear difference in immune response to SARS-CoV-2 using the ANN model of 
full blood count analysis.
Of the 598 patients, only one tested positive for SARS-CoV-2 and for at least one other pathogen; 
that patient also tested positive for Influenza B and for Coronavirus NL63 and was in ICU.
In addition to the changing profile of immune cells, a change in red blood cells and platelets were 
noted. In order to describe the profile of cells, the mean changes were plotted from patients in 
Regular Ward (Supplementary Figure 3). 
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Table 4. Sao Paulo Dataset: table showing number of patients who tested positive for pathogens 
other than SARS-CoV-2, by patient admission (all patients had been tested for SARS-CoV-2 and had 
full blood count results)
Pathogen Community Regular 
ward
Semi 
Intensive 
Ward
ICU Total per 
pathogen
Adenovirus 0 0 0 0 0
Bordetella pertussis 18 1 1 1 21
Chlamydophila 
pneumoniae
1 1 1 0 3
Coronavirus 229E 1 0 0 0 1
Coronavirus HKU1 0 0 0 0 0
Coronavirus NL63 9 1 1 1 12
Coronavirus OC43 3 0 0 0 3
Influenza A H1N1 
2009
2 0 0 0 2
Influenza A 3 0 0 0 3
Influenza B 20 2 2 1 25
Metapneumovirus 0 0 0 0 0
Parainfluenza 1 0 0 0 0 0
Parainfluenza 2 4 1 0 0 5
Parainfluenza 3 4 0 1 0 5
Parainfluenza 4 1 0 0 0 1
Respiratory Syncytial 
Virus
3 0 2 4 9
Rhinovirus 
Enterovirus
78 6 9 5 98
Total 147 12 17 12 188
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Supplementary Figure 1: Scatter plots corresponding to the top four features of patients not 
admitted to hospital (community); categorized by whether tested positive (red) or negative (blue) to rt-
PCR  SARS-CoV-2 test. Dark colors represent averages and error covariance ellipses correspond to 1 
standard deviation.
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Supplementary Figure 2: Scatter plots corresponding to the top four features of patients admitted 
to hospital (regular ward); categorized by whether tested positive (red) or negative (blue) to rt-PCR 
SARS CoV2 test. Dark colors represent averages and error covariance ellipses correspond to 1 
standard deviation. MPV; mean platelet volume, RBC; red blood cells.
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Supplementary Figure 3: Profile of Red Blood Cells and Platelets from patients in Regular Wards 
testing positive (red dot) or negative (blue dot) to rt-PCR for SARS-CoV-2. The difference in means; 
RBC; red blood cells, RBCDW; red blood cell distribution width, MPV; mean platelet volume.
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Discussion
We developed multiple independent models (statistical, random forest and shallow learning) that 
can predict SARS-CoV-2 with an AUC of up to 86% for community and 94% for regular ward patients, 
using only data collected from their normalized full blood counts. This provides an initial screen of 
SARS-CoV-2 positive from negative using biomarkers at an early stage in the disease presentation. 
This screen has been conducted on a set of data based on severity judged by the location of the 
patient in hospital (admitted to the regular ward compared to not admitted to hospital; ICU patients 
were excluded). Hence the models are able to distinguish from altered blood profiles in patients who 
were later diagnosed with other pathogens.
It is well recognised that the symptoms of COVID 19 are accompanied by a significant change in 
immune response19 , with a decreased population of leukocytes, lymphocytes20-21 and eosinophils 19-21 
found throughout all stages of infection. Indeed it was suggested in one case report from Wuhan 
that eosinopenia together with lymphopenia may be a potential indicator for diagnosis22. Other early 
reports used similar predictive patterns found in Full Blood Count parameters, suggesting that 
elevated neutrophil to lymphocyte ratio could be used as part of the diagnosis23. In that study they 
investigated the change in blood parameters in a total of 93 patients (severe and non severe 
collected together), using commonly used ratios used in the diagnosis of viral respiratory diseases 
such as: neutrophil-to-lymphocyte ratio, derived NLR ratio (d-NLR, neutrophil count divided by the 
result of WBC count minus neutrophil count), platelet-to-lymphocyte ratio and lymphocyte-to-
monocyte ratio. However, these parameters commonly alter in respect to other viral infections, and 
we initiated research to identify new ratios to distinguish SARS-CoV-2 from other pathogens. 
Here we show that a new simple calculation based on leukocytes, monocytes, eosinophils and 
platelets (normalized monocytes - leukocytes - eosinophils - platelets) can be used to predict with 
85% AUC the presence of SARS-CoV-2 for early-stage community patients. Further validation will be 
required to determine whether our model can distinguish fully from other pathogens, although 
initial small numbers indicate a trend that is positive.
Leukocytes are a family of white blood cells that includes neutrophils, lymphocytes, monocytes, 
eosinophils and basophils. Specific pathogens induce specific responses, such as an increase in 
circulating neutrophils and monocytes typically increase during sepsis as part of the immune defence 
mechanism, and several studies have indicated that ratios between different blood cells can be used 
to predict outcome. The ratio of monocyte : neutrophil can be used to determine sepsis severity24 , 
and platelet : monocyte aggregation has been reported to be increased in patients with Influenza A 
(H1N1) 25. Indeed, the clinical interest in using the relationship between different parameters of the 
full blood count is of great value and interest due to its simplicity and readily measurable 
parameters. While not yet in common clinical use, it has been shown that neutrophil : lymphocyte 
and mean platelet volume : platelet count could predict the outcome for critically ill patients with 
peritonitis and pancreatitis (bacteremia) 26 . Our results presented here clearly demonstrates that an 
early prediction of those infected with SARS-CoV-2 may be made by the relationship between 
monocytes, eosinophils and leukocytes to differentiate them from other pathogen induced 
infections.
The data analysed in this report focussed on the clear early stages in order to differentiate between 
patients presenting with common symptoms prior to the need to be in ICU. The changes in 
parameters of the full blood count is easily distinguishable from other pathogen-induced infections, 
with an apparent decrease in leukocyte population consisting of a large proportion of monocytes. 
This observation is in keeping with other tools used to diagnose the severity of Covid 19 by the 
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measurement of Il6 which significantly increases throughout the progression of disease. The 
cytokine Il6 is predominantly synthesised by monocytes and macrophage (which derive from 
monocytes), and is partly responsible for the drive of the immune response to deleterious cytokine 
storm.
In order to best understand the immune response to SARS-CoV-2 it is useful to compare it to other 
similar coronaviruses. There are two main example: closest known example is that of SARS-CoV virus 
(SARS) which infected 8096 people and killed 774 in 2002- 2003, and Middle East Respiratory 
syndrome coronavirus (MERS CoV) which in 2013 infected 2102 people and killed 780. The majority 
of all other coronaviruses infect the upper respiratory tract and cause mild respiratory and 
gastrointestinal infections. In contrast, the highly infectious and highly pathogenic coronaviruses 
SARS and MERS were noted to have similar effects on the immune response, and more recently 
overlaps with the pathogenesis now witnessed with SARS-CoV-2 infections. The SARS virus directly 
infects human monocytes, which then produces the cytokines that attract neutrophils, macrophage 
and activated T lymphocytes27; MERS was shown to increase monocytes and their IL6 production28 . 
In parallel, this study indicates that the pathogenesis to SARS-CoV-2 may be linked to monocytes and 
the production of Il6. Here in our study, the analysis of monocyte involvement will be crucial in the 
prediction of SARS-CoV-2 infection. Additionally, use of AI and ML to recognise the altered pattern of 
key blood parameters will be a useful tool in future with the emergence of any future coronavirus 
that is equally pathogenic and contagious.
The decrease in platelets in patients testing positive for SARS-CoV-2 in the regular ward is opposite 
to that observed in separate reports of patients with Influenza A29. A subset of the patients included 
in this analysis were tested for other pathogens, and a proportion of those negative for SARS-CoV-2 
were positive for other pathogens including Coronaviruses (NL63, HKU1 and 229E) and few had 
Influenza A or B. This suggests that platelet count is a good indicator in this predictive model, and 
may be a good way to differentiate SARS-CoV-2 infection from Influenza A. 
The suggests a potential decreased platelet presence in patients, which is of concern due to its link 
to thrombocytopenia and increased internal bleeding. This supports other reports of an increase in 
thrombocytopenia being associated with higher mortality in COVID 19 patients 21. The condition of 
thrombocytopenia may be the reason for the recently noted rashes observed in patients, especially 
young children 30 . However there have been reports that clotting is increased in COVID 19 patients, 
and the data we show is normalised and may be misleading.  This normalised data also indicates an 
increase in platelet size (MPV), which suggests that there is rapid platelet production by the bone 
marrow. Indeed, it is recommended that COVID 19 patients are administered antiplatelet therapy to 
protect against thrombosis31 .  Overall this highlights the difficulty of interpreting mean normalised 
data.
This report is the first to use primary patient data of full blood counts to test and train an ANN to 
predict from patients in a regular ward as well as those in the community who will test positive for 
SARS-CoV2. This preliminary model will be further trained and adapted with the aim to address the 
shortfall in direct SARS-CoV-2 testing methods in hospitals. This will enable a prediction that allows 
health care providers to conduct rapid cheap screening to separate patients into those who are most 
likely to have SARS-COV-2 and those who do not. Early screening allows segregation of patients and 
early treatment intervention.
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Abstract
Since December 2019 the novel coronavirus SARS-CoV-2 has been identified as the cause of the 
pandemic Covid 19. Early symptoms overlap with other common conditions such as common cold 
and Influenza, making early screening and diagnosis are crucial goals for health practitioners. The 
21
aim of the study was to use machine learning, an artificial neural network (ANN) and a simple 
statistical test to identify SARS-CoV-2 positive patients from full blood counts without knowledge of 
symptoms or history of the individuals. The dataset included in the analysis and training contains 
anonymized full blood count results from patients seen at the Hospital Israelita Albert Einstein, at 
São Paulo, Brazil, and who had samples collected to perform the SARS-CoV-2 rt-PCR test during a 
visit to the hospital. Patient data was anonymised by the hospital, clinical data was standardized to 
have a mean of zero and a unit standard deviation. This data was made public with the aim to allow 
researchers to develop ways to enable the hospital to rapidly predict and potentially identify SARS-
CoV-2 positive patients.
We find that with full blood counts random forest, shallow learning and a flexible ANN model predict 
SARS-CoV-2 patients with high accuracy between populations on regular wards (AUC = 93-94%) and 
those not admitted to hospital or in the community (AUC = 80-86%). Here AUC is the Area Under the 
receiver operating characteristics Curve and a measure for model performance. Moreover, a simple 
linear combination of 4 blood counts can be used to have an AUC of 85% for patients within the 
community. The normalised data of different blood parameters from SARS-CoV-2 positive patients 
exhibit a decrease in platelets, leukocytes, eosinophils, basophils and lymphocytes, and an increase 
in monocytes. 
SARS-CoV-2 positive patients exhibit a characteristic immune response profile pattern and changes 
in different parameters measured in the full blood count that are detected from simple and rapid 
blood tests. While symptoms at an early stage of infection are known to overlap with other common 
conditions, parameters of the full blood count can be analysed to distinguish the viral type at an 
earlier stage than current rt-PCR tests for SARS-CoV-2 allow at present. This new methodology has 
potential to greatly improve initial screening for patients where PCR based diagnostic tools are 
limited.
Highlights:
4. Early SARS-CoV-2 prediction from monocytes-leukocytes-eosinophils variable: AUC 84%
5. Prediction in regular ward using machine learning from complete blood count: AUC 94%
6. Predominance of monocytes in SARS-CoV-2 positive patients similar to SARS and MERS
